Skip to content

Transient Ischemic Attack (TIA)

VERSION: 1.0 CREATED: January 27, 2026 STATUS: Approved


DIAGNOSIS: Transient Ischemic Attack (TIA)

ICD-10: G45.9 (Transient cerebral ischemic attack, unspecified), G45.0 (Vertebro-basilar artery syndrome), G45.1 (Carotid artery syndrome), G45.8 (Other transient cerebral ischemic attacks and related syndromes)

CPT CODES: 82962 (Point-of-care glucose), 85025 (CBC with differential), 80053 (CMP (BMP + LFTs)), 85610 (PT/INR), 80061 (Lipid panel (fasting or non-fasting)), 83036 (HbA1c), 84484 (Troponin), 82947 (Blood glucose (fasting)), 84443 (TSH), 85652 (ESR), 83090 (Homocysteine), 80307 (Urine drug screen), 86592 (RPR/VDRL), 87389 (HIV 1/2 antigen/antibody), 84703 (Pregnancy test (β-hCG)), 83735 (Magnesium), 86235 (ANA), 70553 (MRI brain with DWI), 70450 (CT head without contrast), 93000 (ECG (12-lead)), 93228 (Continuous cardiac monitoring (telemetry)), 93306 (Transthoracic echocardiogram (TTE)), 93312 (Transesophageal echocardiogram (TEE)), 93880 (Carotid duplex ultrasound), 93886 (Transcranial Doppler (TCD)), 36224 (Conventional cerebral angiography (DSA))

SYNONYMS: Transient ischemic attack, TIA, mini-stroke, warning stroke, transient stroke, pre-stroke, temporary stroke symptoms, reversible ischemic neurological deficit

SCOPE: Acute evaluation and secondary prevention after transient ischemic attack in adults. Covers risk stratification (ABCD2), urgent workup (MRI with DWI, vascular imaging, cardiac evaluation), dual antiplatelet therapy initiation, and rapid secondary prevention. TIA is a medical emergency — 90-day stroke risk is 10-15% without intervention, highest in first 48h. Excludes completed ischemic stroke (see Acute Ischemic Stroke template), hemorrhagic stroke, and TIA mimics.


PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting

═══════════════════════════════════════════════════════════════ SECTION A: ACTION ITEMS ═══════════════════════════════════════════════════════════════

1. LABORATORY WORKUP

1A. Essential/Core Labs

Test ED HOSP OPD ICU Rationale Target Finding
Point-of-care glucose (CPT 82962) STAT STAT STAT - Hypoglycemia mimics TIA; must rule out immediately >60 mg/dL
CBC with differential (CPT 85025) STAT STAT ROUTINE - Thrombocytosis or thrombocytopenia; polycythemia; anemia; infection Normal
CMP (BMP + LFTs) (CPT 80053) STAT STAT ROUTINE - Electrolytes; renal function for contrast; hepatic function Normal
PT/INR (CPT 85610) STAT STAT ROUTINE - Anticoagulant use; coagulopathy assessment Normal
Lipid panel (fasting or non-fasting) (CPT 80061) STAT STAT ROUTINE - LDL target <70 mg/dL; statin initiation LDL <70
HbA1c (CPT 83036) STAT STAT ROUTINE - Diabetes screening; cardiovascular risk factor <7.0%
Troponin (CPT 84484) STAT STAT - - Concurrent ACS; cardiac embolic source Normal
Blood glucose (fasting) (CPT 82947) - ROUTINE ROUTINE - Diabetes screening <126 mg/dL
TSH (CPT 84443) - ROUTINE ROUTINE - Hyperthyroidism → atrial fibrillation Normal

1B. Extended Workup (Second-line)

Test ED HOSP OPD ICU Rationale Target Finding
ESR (CPT 85652) / CRP (CPT 86140) URGENT ROUTINE ROUTINE - Vasculitis screen; giant cell arteritis (age >50 with TIA); inflammatory markers Normal
Homocysteine (CPT 83090) - ROUTINE ROUTINE - Elevated homocysteine as independent stroke risk factor Normal (<15 µmol/L)
Urine drug screen (CPT 80307) URGENT ROUTINE - - Cocaine/amphetamine-associated TIA/stroke Negative
RPR/VDRL (CPT 86592) - ROUTINE ROUTINE - Syphilitic vasculitis Non-reactive
HIV 1/2 antigen/antibody (CPT 87389) - ROUTINE ROUTINE - HIV-associated vasculopathy Negative
Pregnancy test (β-hCG) (CPT 84703) STAT STAT ROUTINE - Affects imaging and treatment decisions Document result
Magnesium (CPT 83735) URGENT ROUTINE ROUTINE - Electrolyte management Normal

1C. Rare/Specialized (Young TIA or Cryptogenic)

Test ED HOSP OPD ICU Rationale Target Finding
Hypercoagulable panel (Protein C, S, antithrombin III, Factor V Leiden, prothrombin gene mutation) - EXT ROUTINE - Young patient (<50); cryptogenic TIA; personal/family history of thrombosis Normal
Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, β2-glycoprotein I) - ROUTINE ROUTINE - Young TIA; recurrent TIA; systemic lupus; recurrent pregnancy loss Negative
ANA (CPT 86235), dsDNA - EXT ROUTINE - Lupus cerebritis; vasculitis Negative
ANCA (c-ANCA, p-ANCA) - EXT EXT - CNS vasculitis Negative
Hemoglobin electrophoresis - EXT EXT - Sickle cell disease (young patients, African descent) Normal
JAK2 mutation - EXT EXT - Polycythemia vera; myeloproliferative disorders Negative
Lipoprotein(a) - ROUTINE ROUTINE - Independent cardiovascular risk factor; elevated in 20% of population <50 mg/dL

2. DIAGNOSTIC IMAGING & STUDIES

2A. Essential/First-line

Study ED HOSP OPD ICU Timing Target Finding Contraindications
MRI brain with DWI (CPT 70553) STAT STAT URGENT - Within 24h (ideally <6h). DWI-positive in 30-50% of clinical TIA — these patients are at HIGHEST stroke risk and may be reclassified as minor stroke DWI restriction = acute ischemia (even if symptoms resolved, this upgrades risk and may change to minor stroke diagnosis); FLAIR changes; prior infarcts Pacemaker, metallic implants, severe claustrophobia
CT head without contrast (CPT 70450) STAT STAT - - Immediate (if MRI unavailable or contraindicated); excludes hemorrhage and mass No hemorrhage; no mass; may show old infarcts Pregnancy (relative)
CTA head and neck (CPT 70496, 70498) (OR MRA head and neck) STAT STAT URGENT - With initial imaging or within 24h. Evaluates extracranial AND intracranial vessels Carotid stenosis (≥50% NASCET); intracranial stenosis; vertebral stenosis; dissection Contrast allergy; renal impairment (for CTA). MRA: pacemaker
ECG (12-lead) (CPT 93000) STAT STAT ROUTINE - Immediately Atrial fibrillation (detected in 5-10% on initial ECG); atrial flutter; acute MI; LVH; old infarct None
Continuous cardiac monitoring (telemetry) (CPT 93228) STAT STAT - - Minimum 24h in ED/hospital; ideally 48-72h Paroxysmal atrial fibrillation (detected in additional 5-7% with monitoring) None

2B. Extended

Study ED HOSP OPD ICU Timing Target Finding Contraindications
Transthoracic echocardiogram (TTE) (CPT 93306) - ROUTINE ROUTINE - Within 24-48h LV thrombus; PFO; valvular disease; cardiomyopathy; akinetic segments None significant
Transesophageal echocardiogram (TEE) (CPT 93312) with bubble study - ROUTINE ROUTINE - If TTE nondiagnostic; cryptogenic TIA; young patient PFO with right-to-left shunt; atrial septal aneurysm; LAA thrombus; aortic arch atheroma (≥4mm) Esophageal pathology
Carotid duplex ultrasound (CPT 93880) URGENT URGENT URGENT - Within 24h (may be obtained instead of or in addition to CTA/MRA) Carotid stenosis ≥50%; plaque characterization; hemodynamic significance None significant
Extended cardiac monitoring (Holter 30-day or implantable loop recorder) - ROUTINE ROUTINE - Arrange before discharge; especially if cryptogenic TIA Paroxysmal AF (detected in 12-30% with prolonged monitoring in cryptogenic cases) None significant
Transcranial Doppler (TCD) (CPT 93886) with bubble study - ROUTINE ROUTINE - If PFO evaluation needed (alternative to TEE bubble); also for intracranial stenosis and microembolic signals Right-to-left shunt; intracranial stenosis; microembolic signals Absent temporal bone window
CT perfusion - EXT - - If diagnosis uncertain; evaluate for persistent hypoperfusion despite symptom resolution Perfusion deficits suggesting ongoing ischemic risk Contrast allergy; renal impairment

2C. Rare/Specialized

Study ED HOSP OPD ICU Timing Target Finding Contraindications
Conventional cerebral angiography (DSA) (CPT 36224) - EXT EXT - If intracranial stenosis suspected on CTA/MRA; vasculitis workup; Moyamoya Beading (vasculitis); intimal flap (dissection); Moyamoya collaterals; intracranial stenosis quantification Contrast allergy; coagulopathy
MRI vessel wall imaging - EXT EXT - Intracranial stenosis characterization; vasculitis evaluation Vessel wall enhancement (active inflammation, unstable plaque) Standard MRI contraindications
Fat-saturated MRI neck - ROUTINE ROUTINE - If cervical dissection suspected (neck pain, Horner syndrome, young patient) Intramural hematoma (crescent sign) Standard MRI contraindications
PET-CT - - EXT - If occult malignancy suspected (Trousseau syndrome) Malignancy Pregnancy

3. TREATMENT

3A. Acute/Emergent

Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU
Aspirin (loading dose) PO - 325 mg :: PO :: load :: 325 mg PO loading dose immediately upon TIA diagnosis (give in ED). Do NOT delay antiplatelet therapy Active GI bleed; true aspirin allergy; thrombocytopenia <50K GI symptoms; bleeding STAT STAT STAT -
Clopidogrel (loading dose for DAPT) PO - 300 mg :: PO :: load :: 300 mg PO loading dose (give with aspirin for DAPT). DAPT is standard for high-risk TIA (ABCD2 ≥4) or minor stroke per CHANCE and POINT trials Active bleeding; severe hepatic impairment Bleeding; CBC STAT STAT STAT -
Dual antiplatelet therapy (DAPT maintenance): Aspirin + Clopidogrel - - 81 mg :: - :: daily :: Aspirin 81 mg daily + Clopidogrel 75 mg daily x 21 days (CHANCE protocol) or x 90 days (POINT protocol — higher bleeding risk with longer duration). Then transition to single antiplatelet (typically clopidogrel 75 mg or aspirin 81 mg monotherapy) Major bleeding risk; planned surgery Bleeding signs; CBC monthly - STAT STAT -
Dual antiplatelet therapy (alternative): Aspirin + Ticagrelor PO - 81 mg :: PO :: daily :: Aspirin 81 mg daily + Ticagrelor 90 mg BID x 30 days (THALES trial; for minor stroke NIHSS ≤5). Then single antiplatelet Intracranial hemorrhage history; high bleeding risk; hepatic impairment Bleeding; dyspnea (common side effect); avoid strong CYP3A4 inhibitors - STAT STAT -
High-intensity statin PO - 80 mg :: PO :: daily :: Atorvastatin 80 mg PO daily (or Rosuvastatin 20-40 mg). Start immediately regardless of baseline LDL Active liver disease; pregnancy LFTs at 12 weeks; lipid panel at 4-12 weeks; CK if myalgia STAT STAT STAT -
Blood pressure management (acute) - - 25% :: - :: - :: If SBP >220 or DBP >120 in ED: lower gently (15-25% in first 24h). If lower BP levels: permissive hypertension in first 24-48h unless end-organ damage. Avoid precipitous drops Carotid stenosis with hemodynamic TIA: do NOT aggressively lower BP (may worsen symptoms) Neuro checks with each change; BP q1h acutely STAT STAT - -

3B. Secondary Prevention (Initiate Urgently)

Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU
Antihypertensive therapy (chronic) PO - 10-20 mg :: PO :: daily :: Target BP <130/80 mmHg. Start/restart 24-48h after TIA once stable. Agent choice per comorbidities: ACE-I/ARB first-line. Consider: Lisinopril 10-20 mg daily, Amlodipine 5-10 mg, Losartan 50-100 mg, Chlorthalidone 12.5-25 mg Bilateral renal artery stenosis (ACE-I/ARB); pregnancy Home BP monitoring; Cr and K+ at 1-2 weeks - ROUTINE ROUTINE -
Anticoagulation (if atrial fibrillation detected) PO - 5 mg :: - :: BID :: Start DOAC within 1-3 days for TIA (can start earlier than stroke). Preferred: Apixaban 5 mg BID (2.5 mg BID if criteria met). Alternative: Rivaroxaban 20 mg daily; Dabigatran 150 mg BID. Discontinue antiplatelet when anticoagulant started (do NOT combine long-term unless specific indication) Active bleeding; mechanical valve (use warfarin); severe renal impairment Renal function q6-12 months; bleeding signs - ROUTINE ROUTINE -
Carotid endarterectomy (CEA) Surgery - 50% :: - :: - :: For symptomatic carotid stenosis ≥50% (NASCET criteria); ideally performed within 2 weeks of TIA (maximum benefit). NNT = 6 for 70-99% stenosis; NNT = 22 for 50-69% stenosis Near-occlusion (controversial); life expectancy <5 years; severe cardiac comorbidity Post-op: BP monitoring; neuro checks q1h x 24h; wound hematoma; cranial nerve injury - URGENT URGENT -
Carotid artery stenting (CAS) Endovascular - N/A :: Endovascular :: per protocol :: Alternative to CEA if: high surgical risk, prior neck radiation, prior CEA with restenosis, surgically inaccessible. Requires DAPT (aspirin + clopidogrel) post-stenting Severe aortic arch tortuosity; fresh thrombus Post-procedure: BP management; neuro checks; DAPT compliance; restenosis surveillance - ROUTINE ROUTINE -
PFO closure Procedure - N/A :: Procedure :: per protocol :: For cryptogenic TIA/stroke age 18-60 with PFO and right-to-left shunt. Reduces recurrent stroke vs medical therapy alone (CLOSE, RESPECT, REDUCE trials). Requires 3-6 months DAPT then aspirin indefinitely Anatomic constraints; active infection Echo at 6-12 months; aspirin long-term - - ROUTINE -
Ezetimibe PO - 10 mg :: PO :: daily :: 10 mg PO daily; add if LDL not at goal on max statin LFTs; lipid panel - - ROUTINE ROUTINE -
PCSK9 inhibitor (evolocumab or alirocumab) SC - 140 mg :: SC :: monthly :: Evolocumab 140 mg SC q2 weeks or 420 mg monthly; if LDL not at goal on statin + ezetimibe Lipid panel q4-12 weeks; injection site - - - ROUTINE -
Diabetes management (optimize) PO/SC - 7% :: - :: - :: Target HbA1c <7% (individualized); GLP-1 agonists and SGLT2 inhibitors have cardiovascular benefit Per agent HbA1c q3 months; renal function - ROUTINE ROUTINE -

3C. Medications for Specific Etiologies

Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU
Anticoagulation (warfarin) - Mechanical heart valve + TIA N/A :: - :: per protocol :: Warfarin to target INR 2.5-3.5; bridge with heparin - INR weekly then monthly - - - -
DAPT long-term (aspirin + clopidogrel) - Intracranial stenosis 70-99% (SAMMPRIS trial: medical > stenting) 325 mg :: PO :: daily :: Aspirin 325 mg + clopidogrel 75 mg daily x 90 days; then single antiplatelet + aggressive risk factor management - Bleeding; MRA q6-12 months - - - -
Anticoagulation - Cervical artery dissection N/A :: - :: per protocol :: Antiplatelet or anticoagulation (both equally effective per CADISS trial); typically 3-6 months - Repeat vascular imaging at 3-6 months - - - -
Colchicine PO Residual inflammatory risk (LoDoCo2 / COLCOT trials support in ACS — emerging data for stroke prevention) 0.5 mg :: PO :: daily :: 0.5 mg PO daily - GI symptoms; CBC - - - -

4. OTHER RECOMMENDATIONS

4A. Referrals & Consults

Recommendation ED HOSP OPD ICU Indication
Neurology (stroke team) STAT STAT URGENT - All TIA patients; risk stratification; workup direction; secondary prevention
Vascular surgery - URGENT URGENT - Symptomatic carotid stenosis ≥50% for CEA; ideally within 2 weeks
Neurointerventional / Endovascular - ROUTINE ROUTINE - Carotid stenting; intracranial stenosis management; PFO closure referral
Cardiology - ROUTINE ROUTINE - Newly detected AF; PFO evaluation; anticoagulation management; cardiac optimization
Electrophysiology - ROUTINE ROUTINE - Extended cardiac monitoring arrangement; AF management
Primary care (expedited) - ROUTINE ROUTINE - Risk factor management; medication titration; chronic disease management
Smoking cessation program - ROUTINE ROUTINE - Active smokers
Nutrition / Dietitian - ROUTINE ROUTINE - Mediterranean/DASH diet counseling; weight management
Diabetes educator - - ROUTINE - If new or uncontrolled diabetes
Social work - ROUTINE ROUTINE - Medication assistance; transportation; caregiver support

4B. Patient Instructions

Recommendation ED HOSP OPD
TIA is a WARNING — risk of full stroke is HIGHEST in first 48h; take this very seriously STAT STAT ROUTINE
Call 911 IMMEDIATELY if any symptom recurs: sudden weakness, numbness, speech difficulty, vision changes, severe headache, loss of balance (F.A.S.T.) STAT STAT ROUTINE
Take all medications EXACTLY as prescribed; do NOT stop aspirin, clopidogrel, or statin without medical guidance STAT STAT ROUTINE
Do NOT drive for at least 2 weeks (state laws vary; some require neurologist clearance) URGENT URGENT ROUTINE
Return for follow-up within 1-2 weeks with neurology; primary care within 2-4 weeks - ROUTINE ROUTINE
Blood pressure monitoring at home daily; keep log; target per physician guidance (<130/80) - ROUTINE ROUTINE
Report any bleeding (bruising, blood in stool/urine, nosebleed) while on DAPT - ROUTINE ROUTINE
Carry updated medication list at all times - ROUTINE ROUTINE
Notify all providers of TIA history (dental, surgical, emergency) - ROUTINE ROUTINE

4C. Lifestyle & Prevention

Recommendation ED HOSP OPD
Smoking cessation (ABSOLUTE — doubles stroke risk) - ROUTINE ROUTINE
Blood pressure target <130/80 mmHg - ROUTINE ROUTINE
LDL target <70 mg/dL (high-intensity statin) - ROUTINE ROUTINE
Mediterranean or DASH diet - ROUTINE ROUTINE
Sodium restriction <2.3 g/day (ideally <1.5 g) - ROUTINE ROUTINE
Regular aerobic exercise: 40 min moderate intensity, 3-4 days/week (after medical clearance) - - ROUTINE
Weight management (BMI 18.5-24.9) - ROUTINE ROUTINE
Alcohol limitation: ≤1 drink/day women, ≤2 drinks/day men - ROUTINE ROUTINE
HbA1c target <7% (individualized) - ROUTINE ROUTINE
OSA screening (STOP-BANG); CPAP if diagnosed - ROUTINE ROUTINE
Depression / anxiety screening (PHQ-9) - - ROUTINE

═══════════════════════════════════════════════════════════════ SECTION B: REFERENCE (Expand as Needed) ═══════════════════════════════════════════════════════════════

5. DIFFERENTIAL DIAGNOSIS

Alternative Diagnosis Key Distinguishing Features Tests to Differentiate
Migraine with aura Gradual onset ("marching" symptoms over minutes); visual aura (scintillating scotoma); headache follows; younger; history of migraine Normal MRI DWI; clinical history; gradual onset differentiates from sudden TIA
Seizure with Todd's paralysis Witnessed seizure; post-ictal confusion; resolves in hours; focal weakness post-seizure EEG; MRI DWI negative; clinical history
Hypoglycemia Glucose <60; diaphoresis; tremor; confusion; resolves with glucose POC glucose
Peripheral vertigo (BPPV, vestibular neuritis) Isolated vertigo without other neurologic deficits; positive HINTS (peripheral pattern); nystagmus characteristics HINTS exam; MRI DWI negative; normal CTA
Multiple sclerosis exacerbation Young patient; symptoms disseminated in space and time; prior episodes; weeks duration MRI brain (periventricular/juxtacortical lesions); oligoclonal bands
Brain tumor Subacute progressive symptoms; headache; may have transient symptoms from seizure or compression MRI with contrast (enhancing mass)
Conversion disorder / FND Non-anatomic deficit distribution; Hoover sign; give-way weakness; psychological stressor Normal MRI; normal vascular imaging; clinical exam
Syncope / Pre-syncope Loss of consciousness; lightheadedness; no focal neurologic deficit Orthostatic vitals; ECG; echo; tilt table
Labyrinthine infarction Isolated sudden hearing loss + vertigo (AICA territory); may be a TIA equivalent Audiometry (sensorineural hearing loss); MRI DWI (may show pontine or cerebellar infarct)
Subdural hematoma Fluctuating symptoms; trauma history or anticoagulation; subacute CT (extra-axial collection)
Transient global amnesia Isolated anterograde amnesia lasting hours; no motor or speech deficit; age >50; benign Clinical presentation; MRI DWI (may show small hippocampal DWI lesions)
Metabolic encephalopathy Bilateral, non-focal; confusion predominant; abnormal labs BMP; ammonia; LFTs; TSH

6. MONITORING PARAMETERS

Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal
Neurologic exam (deficit recurrence) STAT STAT ROUTINE - q1h x 6h, then q4h in hospital; each outpatient visit No recurrence of symptoms If symptoms recur: STAT MRI DWI; may need admission; upgrade to stroke protocol if persistent >24h or DWI+
Blood pressure STAT STAT ROUTINE - q1h x 6h in ED; q4h in hospital; daily at home Acute: avoid precipitous drop; Chronic: <130/80 Antihypertensive titration; avoid SBP <100 if carotid stenosis
Heart rhythm (telemetry) STAT STAT - - Continuous x 24-72h minimum Sinus rhythm; detect paroxysmal AF If AF detected: anticoagulation; discontinue antiplatelet
Blood glucose STAT ROUTINE ROUTINE - q6h in hospital; HbA1c at follow-up 140-180 (acute); HbA1c <7% Diabetes management
Lipid panel - ROUTINE ROUTINE - Baseline; repeat at 4-12 weeks on statin LDL <70 mg/dL Intensify statin; add ezetimibe or PCSK9i
Renal function (Cr) - ROUTINE ROUTINE - At baseline; after starting ACE-I/ARB Stable Dose adjust medications
CBC - ROUTINE ROUTINE - Baseline; at 1 month on DAPT Normal Monitor for bleeding on DAPT
ABCD2 Score (at presentation) STAT - - - Once (risk stratification) Score determines urgency and disposition ≥4: admit or rapid TIA clinic within 24h; <4: may discharge with 24-48h follow-up if imaging complete
Extended cardiac monitoring - ROUTINE ROUTINE - 30-day Holter or ILR post-discharge (especially cryptogenic) Detect AF Anticoagulation if AF detected
Carotid imaging follow-up - - ROUTINE - After CEA/CAS: duplex at 1 month, 6 months, then annually No restenosis Repeat intervention if significant restenosis

7. DISPOSITION CRITERIA

Disposition Criteria
Admit to hospital (preferred for high-risk) ABCD2 ≥4; crescendo TIA (recurrent within 24h); large vessel stenosis identified; atrial fibrillation detected; DWI-positive on MRI; incomplete workup that cannot be completed within 24h as outpatient
Rapid TIA clinic / 24-48h outpatient workup ABCD2 <4; symptoms fully resolved; no large vessel disease on imaging; no AF on ECG; MRI/CTA completed and negative; reliable follow-up; medications started
Discharge from ED (with next-day follow-up) Low risk (ABCD2 0-3); all imaging completed and normal (MRI DWI negative, CTA normal, ECG sinus); medications started; reliable patient; follow-up within 24-48h guaranteed
Admit to ICU Rarely needed; consider if hemodynamic TIA with critical stenosis; malignant hypertension; crescendo TIA progressing to stroke
Transfer to stroke center If vascular imaging, MRI, or neurology consultation not available within 24h

8. EVIDENCE & REFERENCES

Recommendation Evidence Level Source
DAPT (aspirin + clopidogrel 21 days) for minor stroke / high-risk TIA Class I, Level A CHANCE trial (Wang et al. NEJM 2013)
DAPT (aspirin + clopidogrel 90 days) for minor stroke / high-risk TIA Class IIa, Level B POINT trial (Johnston et al. NEJM 2018); higher ICH risk than 21 days
Aspirin + ticagrelor x 30 days for minor stroke (NIHSS ≤5) Class IIa, Level B THALES trial (Johnston et al. NEJM 2020)
High-intensity statin for TIA secondary prevention Class I, Level A SPARCL trial (Amarenco et al. NEJM 2006); AHA/ASA 2021
LDL target <70 mg/dL Class I, Level A TST trial (Amarenco et al. NEJM 2020)
BP target <130/80 for secondary prevention Class I, Level A SPS3 trial; PROGRESS; AHA/ASA 2021
CEA within 2 weeks for symptomatic stenosis ≥50% Class I, Level A NASCET (NEJM 1991); ECST; Rothwell et al. (Lancet 2004) — maximum benefit if performed within 2 weeks
DOACs preferred over warfarin for AF-related TIA/stroke Class I, Level A RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE AF
Extended cardiac monitoring for cryptogenic TIA Class IIa, Level B CRYSTAL-AF (Sanna et al. NEJM 2014); EMBRACE (Gladstone et al. NEJM 2014)
PFO closure for cryptogenic stroke/TIA age 18-60 Class IIa, Level B CLOSE, RESPECT, REDUCE trials
MRI DWI within 24h (DWI+ = higher stroke risk) Class I, Level B AHA/ASA Guidelines; Coutts et al. (Stroke 2012)
ABCD2 score for risk stratification Class IIa, Level B Johnston et al. (Lancet 2007); useful but imperfect; imaging adds value
Rapid TIA evaluation reduces 90-day stroke risk Class I, Level B EXPRESS trial (Rothwell et al. Lancet 2007); SOS-TIA (Lavallée et al. Lancet Neurol 2007)
Medical therapy superior to stenting for intracranial stenosis Class I, Level A SAMMPRIS trial (Chimowitz et al. NEJM 2011)
OSA screening and CPAP Class IIa, Level B AHA/ASA 2021 Guidelines

APPENDIX: ABCD2 SCORE (TIA RISK STRATIFICATION)

Component Points
Age ≥60 1
BP ≥140/90 at presentation 1
Clinical features: Unilateral weakness 2
Clinical features: Speech impairment without weakness 1
Duration ≥60 min 2
Duration 10-59 min 1
Diabetes 1
Total possible 7
Score 2-Day Stroke Risk 90-Day Stroke Risk Recommendation
0-3 (Low) 1.0% 3.1% Rapid outpatient workup within 24-48h; may discharge from ED if workup complete
4-5 (Moderate) 4.1% 9.8% Admit or ensure <24h follow-up; start DAPT
6-7 (High) 8.1% 17.8% Admit; aggressive workup and treatment

Note: ABCD2 is imperfect as a stand-alone tool. DWI-positive MRI, large vessel stenosis, and AF detection independently predict stroke risk regardless of ABCD2 score.

APPENDIX: SECONDARY PREVENTION CHECKLIST

Risk Factor Target Intervention
Blood pressure <130/80 ACE-I/ARB + lifestyle
LDL cholesterol <70 mg/dL High-intensity statin + ezetimibe ± PCSK9i
Diabetes (HbA1c) <7.0% Metformin; GLP-1/SGLT2 (CV benefit)
Antiplatelet DAPT x 21-90 days → monotherapy Aspirin + clopidogrel → single agent
Anticoagulation (if AF) DOAC Apixaban preferred
Carotid stenosis ≥50% Revascularization CEA within 2 weeks; or CAS
Smoking Cessation Counseling + pharmacotherapy
Exercise 40 min, 3-4x/week Cardiac clearance first
Diet Mediterranean/DASH Dietitian referral
BMI 18.5-24.9 Comprehensive lifestyle
Sleep apnea Screening; CPAP if positive STOP-BANG; sleep study